Welcome to our dedicated page for Ibio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iBio, Inc. filings document material events for an AI-driven biotechnology company developing precision antibody therapies. Recent Form 8-K disclosures cover clinical and regulatory updates for IBIO-600, preclinical data for IBIO-610, quarterly financial results, Regulation FD communications and other pipeline-related events.
The company's filings also record capital-structure matters involving common stock, pre-funded warrants and Series G warrants, along with shareholder voting results, board composition, committee appointments and governance items disclosed through annual-meeting and material-event reports.
iBio, Inc. reported third-quarter fiscal 2026 results, highlighting pipeline progress alongside wider losses. The company recorded no revenue for the quarter ended March 31, 2026, while research and development expenses rose to $3.3 million from $1.9 million and general and administrative expenses increased to $5.1 million from $3.0 million, driven mainly by a $2.5 million impairment of the IBIO-101 intangible asset.
Operating loss was $8.4 million and net loss was $7.7 million, or $0.06 per share, compared with a $4.9 million net loss, or $0.49 per share, a year earlier. iBio held $74.8 million in cash, cash equivalents and investments in debt securities as of March 31, 2026, and received approximately $17 million in gross proceeds from warrant exercises in the fourth fiscal quarter, which the company states extend its cash runway into the fourth quarter of fiscal 2028.
Strategically, iBio obtained regulatory clearance in Australia to initiate a phase 1 clinical trial of obesity candidate IBIO-600, reported new obese non-human primate data for IBIO-610 showing a 6.7% reduction in visceral fat and 5.2% reduction in total fat mass, and expanded its pipeline with a bispecific antibody targeting pulmonary hypertension associated with heart failure with preserved ejection fraction.
iBio, Inc. reported changes to its Board of Directors. The Board appointed Dr. Elizabeth Stoner as a Class II director and member of the Compensation Committee, effective May 7, 2026, with a term running until the 2028 annual meeting of stockholders.
Dr. Stoner brings more than 35 years of biotech R&D leadership, including senior roles at Merck Research Laboratories, Semma Therapeutics, and Rhythm Pharmaceuticals, and currently serves as an Entrepreneur Partner at MPM BioImpact. She joins as an independent director, while Evert (Eef) Schimmelpennink resigned from the Board and the Compensation Committee, with the company stating his resignation was not due to any disagreement over operations, policies, or practices.
For the fiscal year ending June 30, 2026, Dr. Stoner will receive the Company’s standard non-employee director compensation, including a $40,000 annual Board fee, a $7,500 annual Compensation Committee fee, and eligibility for an initial stock option grant vesting over 36 months, along with future equity awards under standard policies.
iBio, Inc. filed a prospectus supplement updating a resale registration that covers 11,061,738 shares of its common stock. The supplement substitutes SILV Fund Ltd for Point72 Associates, LLC as a selling stockholder following a transfer of 876,340 shares.
The supplement amends the "Selling Stockholders" table to reflect the transfer and shows entities affiliated with Sirenia Capital Management LP beneficially own 11,604,590 shares ( 9.99%). The supplement reiterates the Prospectus terms and states the Nasdaq last sale price was $1.63 on April 28, 2026.
iBio, Inc. filed an amended report to correct and update details about its Series G warrants and related share counts, and to describe progress on its IBIO-600 program. The amendment clarifies that Series G warrants to purchase up to 35,770,000 shares of common stock now expire at 5:00 p.m. New York City time on May 20, 2026, based on a recent clinical milestone announcement.
The company previously issued pre-funded warrants for up to 71,540,000 shares and matching Series G and Series H warrants in an August 2025 financing. As of April 17, 2026, Series G warrants to buy up to 11,065,000 shares remain outstanding, and common shares outstanding total 36,143,561. The filing also notes Australian regulatory and ethics approvals enabling a first-in-human Phase 1 clinical trial of IBIO-600, with first participants expected to be dosed in the second quarter of 2026.
iBio, Inc. announced it has received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, enabling initiation of a first-in-human Phase 1 trial of IBIO-600 in overweight and obese adults in Australia. The company expects to dose the first participant in the second quarter of 2026. IBIO-600 is a long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition, potentially complementing GLP-1 therapies. The filing also explains that, following this public announcement, outstanding Series G warrants to purchase up to 27,945,000 shares of common stock will now expire on May 12, 2026, while any Series H warrants issued upon their exercise will expire four years after the 2025 offering closing.
iBio, Inc. insider activity: Chief Legal Officer Banjak Marc reported open-market purchases of iBio common stock. On March 26, 2026, he bought 12,500 shares at $1.6425 per share and another 1,434 shares at $1.76 per share.
After these two purchases, his directly held position increased to 25,000 shares of iBio common stock, with no sales or derivative transactions reported in this filing.
iBio, Inc.’s Chief Financial Officer Felipe Duran purchased 24,835 shares of common stock in the open market. The transactions occurred on March 19, 2026 at prices ranging from $2.01 to $2.02 per share, with a weighted average purchase price of $2.0186.
Following these purchases, Duran directly owns 35,974 shares of iBio common stock. The filing notes that the shares were acquired through multiple trades within the price range, and the CFO has committed to provide detailed trade breakdowns upon request.
iBio, Inc. director and officer Martin Brenner bought 12,336 shares of common stock in an open-market transaction at $2.02 per share. This was a direct purchase, classified as a routine open-market buy.
Following this transaction, Brenner directly owns 30,652 shares of iBio common stock.
iBio, Inc. filed a Form 8-K describing new preclinical results for IBIO-610, an Activin E antibody candidate being studied for fat-selective weight loss. In obese non-human primates, two once-every-eight-week doses reduced visceral fat by 6.7% and total fat mass by 5.2% despite a high-calorie diet, with only a slight increase in lean mass.
These findings, consistent with prior rodent data and other Activin E–targeting approaches in human trials, support continued evaluation of IBIO-610 for obesity, cardiometabolic and cardiopulmonary diseases. iBio also highlighted strategic expansion into the cardiopulmonary field, including a myostatin x Activin A bispecific antibody program for pulmonary hypertension heart failure with preserved ejection fraction (PH-HFpEF), in an updated corporate presentation.